Ming-Xiang Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ming-Xiang Zhang has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
Jie Cheng
National Key Laboratory for Innovation and Transformation of Luobing Theory; The Key Laboratory of Cardiovascular Remodeling and Function Research, Department of Cardiology, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Qilu Hospital of Shandong University, Jinan, China
11 shared publicationsWei Zhang
Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Qilu Hospital of Shandong University, Jinan, China
11 shared publicationsBin Liu
Department of Emergency and Chest Pain Center, Qilu Hospital of Shandong University, Jinan, China 202162099743@.sdu.edu.cn
10 shared publicationsFei Xie
Qilu Hospital of Shandong University
10 shared publicationsWen Qiao
The Key Laboratory of Cardiovascular Remodelling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China
9 shared publicationsYa-Min Hou
National Key Laboratory for Innovation and Transformation of Luobing Theory; The Key Laboratory of Cardiovascular Remodeling and Function Research, Department of Cardiology, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Qilu Hospital of Shandong University, Jinan, China
8 shared publications
Latest Publications
- 22 April 2026
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 23 (6) , 654-672
Interleukin enhancer binding factor 3 exacerbates cardiac inflammation and injury following myocardial infarction by inhibiting Lys48-linked ubiquitination on HNRNPA2B1 in macrophages
Changes in the immune microenvironment are key features of ischemic heart disease. In particular, excessive inflammatory responses driven by macrophages are the primary cause of myocardial injury, impaired repair and deterioration of cardiac function following myocardial infarction (MI). We report that interleukin enhancer binding factor 3 (ILF3) is a key regulator that mediates immune responses in macrophages. We found that ILF3 expression was significantly upregulated in macrophages from AMI patients and animal models. This was accompanied by increased levels of inflammation and cardiac dysfunction. ILF3 deficiency in myocardial infarction mice promoted the resolution of inflammatory responses while improving cardiac function and mitigating adverse remodeling. Mechanistically, macrophage ILF3 inhibits Trim21-mediated ubiquitination and degradation of HNRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2B1) at lysine 112 through binding to the RRM1 and RRM2 domains of HNRNPA2B1. The ILF3/HNRNPA2B1 axis enhances the stability of Irak4 mRNA through m6A modification, activating the c-jun/c-fos pathway, leading to early inflammatory responses following MI, and promoting myocardial injury and adverse remodeling after infarction. Finally, our results suggest that targeting HNRNPA2B1 and Irak4 effectively improves myocardial injury and cardiac repair post-MI. In summary, our findings underscore the critical role of macrophage ILF3 in mediating postinfarction inflammation in myocardial injury. These findings suggest that inhibition of macrophage ILF3 may be an important target for the treatment of ischemic myocardial injury and inflammation. During the inflammatory phase of myocardial infarction, ILF3 levels are elevated in macrophages. Macrophage ILF3 inhibits the ubiquitination and degradation of HNRNPA2B1. The latter increases the stability of Irak4 mRNA through m6A modification, activating the c-jun/c-fos pathway, leading to early inflammatory responses, and promoting myocardial injury and adverse remodeling. When ILF3 is absent in macrophages, HNRNPA2B1 is degraded by Trim21-mediated ubiquitination, subsequently inhibiting inflammation-related signaling pathways, alleviating myocardial damage, and promoting repair.
- 22 April 2026
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 23 (6) , 654-672
Interleukin enhancer binding factor 3 exacerbates cardiac inflammation and injury following myocardial infarction by inhibiting Lys48-linked ubiquitination on HNRNPA2B1 in macrophages
Changes in the immune microenvironment are key features of ischemic heart disease. In particular, excessive inflammatory responses driven by macrophages are the primary cause of myocardial injury, impaired repair and deterioration of cardiac function following myocardial infarction (MI). We report that interleukin enhancer binding factor 3 (ILF3) is a key regulator that mediates immune responses in macrophages. We found that ILF3 expression was significantly upregulated in macrophages from AMI patients and animal models. This was accompanied by increased levels of inflammation and cardiac dysfunction. ILF3 deficiency in myocardial infarction mice promoted the resolution of inflammatory responses while improving cardiac function and mitigating adverse remodeling. Mechanistically, macrophage ILF3 inhibits Trim21-mediated ubiquitination and degradation of HNRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2B1) at lysine 112 through binding to the RRM1 and RRM2 domains of HNRNPA2B1. The ILF3/HNRNPA2B1 axis enhances the stability of Irak4 mRNA through m6A modification, activating the c-jun/c-fos pathway, leading to early inflammatory responses following MI, and promoting myocardial injury and adverse remodeling after infarction. Finally, our results suggest that targeting HNRNPA2B1 and Irak4 effectively improves myocardial injury and cardiac repair post-MI. In summary, our findings underscore the critical role of macrophage ILF3 in mediating postinfarction inflammation in myocardial injury. These findings suggest that inhibition of macrophage ILF3 may be an important target for the treatment of ischemic myocardial injury and inflammation. During the inflammatory phase of myocardial infarction, ILF3 levels are elevated in macrophages. Macrophage ILF3 inhibits the ubiquitination and degradation of HNRNPA2B1. The latter increases the stability of Irak4 mRNA through m6A modification, activating the c-jun/c-fos pathway, leading to early inflammatory responses, and promoting myocardial injury and adverse remodeling. When ILF3 is absent in macrophages, HNRNPA2B1 is degraded by Trim21-mediated ubiquitination, subsequently inhibiting inflammation-related signaling pathways, alleviating myocardial damage, and promoting repair.
- 11 November 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 394 (Pt B) , 120645
Association between the atherogenic index of plasma and risk of depression in patients with diabetes: a cross-sectional study
- 11 November 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 394 (Pt B) , 120645
Association between the atherogenic index of plasma and risk of depression in patients with diabetes: a cross-sectional study
- 24 June 2025
- Published by Taylor & Francis in Autophagy
- Vol. 21 (12) , 2650-2669
Macrophage TRIM21 knockout inhibits septic acute lung injury by downregulating autophagy regulator protein ubiquitination
Acute lung injury (ALI) caused by sepsis is a fatal disease characterized by an systemic inflammatory response to invading pathogens. Inducing macrophage macroautophagy/autophagy is a critical strategy to combat the inflammatory response in septic ALI. The E3 ubiquitin ligase TRIM21 plays important roles in autophagy. However, the mechanism connecting macrophage TRIM21-associated autophagy to ALI development remains unclear. Therefore, this study was aimed to investigate the role of macrophage TRIM21 in septic ALI in human and mice. TRIM21 levels were significantly increased in the macrophages of septic mice and in the peripheral blood mononuclear cells and bronchoalveolar lavage fluid of septic ALI patients relative to the controls. Intriguingly, Trim21-specific agonist administration exacerbated ALI and inflammatory responses in septic mice. To elucidate the role of macrophage TRIM21 in the development of septic ALI, we developed a clinically relevant macrophage trim21-specific knockout mouse sepsis model (trim21M-KO). trim21 deficiency significantly reduced mortality in septic ALI model mice by inhibiting sepsis-induced pulmonary edema and inflammatory infiltration, thereby improving the mechanical barrier properties of the alveolar mucosal epithelium and permeability of the alveolar membrane. Mechanistically, TRIM21 inhibits macrophage autophagy by enhancing the K11-linked ubiquitination of the autophagy-regulating proteins ULK1, SQSTM1/p62, BECN1/beclin1, and MAP1LC3B/LC3B and accelerating their ubiquitination-dependent proteasome degradation. This further promotes pro-inflammatory M1 macrophage polarization, aggravating the inflammation of septic lung tissue and exacerbating ALI. Collectively, our data demonstrate a novel role for macrophage TRIM21 in mediating autophagy to accelerate septic ALI. These new findings may provide a framework for potential interventions against septic ALI.
- 24 June 2025
- Published by Taylor & Francis in Autophagy
- Vol. 21 (12) , 2650-2669
Macrophage TRIM21 knockout inhibits septic acute lung injury by downregulating autophagy regulator protein ubiquitination
Acute lung injury (ALI) caused by sepsis is a fatal disease characterized by an systemic inflammatory response to invading pathogens. Inducing macrophage macroautophagy/autophagy is a critical strategy to combat the inflammatory response in septic ALI. The E3 ubiquitin ligase TRIM21 plays important roles in autophagy. However, the mechanism connecting macrophage TRIM21-associated autophagy to ALI development remains unclear. Therefore, this study was aimed to investigate the role of macrophage TRIM21 in septic ALI in human and mice. TRIM21 levels were significantly increased in the macrophages of septic mice and in the peripheral blood mononuclear cells and bronchoalveolar lavage fluid of septic ALI patients relative to the controls. Intriguingly, Trim21-specific agonist administration exacerbated ALI and inflammatory responses in septic mice. To elucidate the role of macrophage TRIM21 in the development of septic ALI, we developed a clinically relevant macrophage trim21-specific knockout mouse sepsis model (trim21M-KO). trim21 deficiency significantly reduced mortality in septic ALI model mice by inhibiting sepsis-induced pulmonary edema and inflammatory infiltration, thereby improving the mechanical barrier properties of the alveolar mucosal epithelium and permeability of the alveolar membrane. Mechanistically, TRIM21 inhibits macrophage autophagy by enhancing the K11-linked ubiquitination of the autophagy-regulating proteins ULK1, SQSTM1/p62, BECN1/beclin1, and MAP1LC3B/LC3B and accelerating their ubiquitination-dependent proteasome degradation. This further promotes pro-inflammatory M1 macrophage polarization, aggravating the inflammation of septic lung tissue and exacerbating ALI. Collectively, our data demonstrate a novel role for macrophage TRIM21 in mediating autophagy to accelerate septic ALI. These new findings may provide a framework for potential interventions against septic ALI.
- Open Access
- 23 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Macrophage ILF3 promotes abdominal aortic aneurysm by inducing inflammatory imbalance in male mice
Imbalance of proinflammatory and anti-inflammatory responses plays a crucial role in the progression of abdominal aortic aneurysms. ILF3, a known modulator of the innate immune response, is involved in cardiovascular diseases. This study aims to investigate the role of ILF3 in abdominal aortic aneurysm formation. Here, we use multi-omics analyzes, transgenic male mice, and multiplex immunohistochemistry to unravel the underlying involvement of ILF3 in abdominal aortic aneurysms. The results show that macrophage ILF3 deficiency attenuates abdominal aortic aneurysm progression, while elevated macrophage ILF3 exacerbates abdominal aortic aneurysm lesions. Mechanistically, we reveal that macrophagic ILF3 increases NF-κB activity by hastening the decay of p105 mRNA, leading to amplified inflammation in macrophages. Meanwhile, ILF3 represses the anti-inflammatory action by inhibiting the Keap1-Nrf2 signaling pathway through facilitating the ILF3/eIF4A1 complex-mediated enhancement of Keap1 translational efficiency. Moreover, Bardoxolone Methyl treatment alleviates the severity of abdominal aortic aneurysm lesions in the context of elevated ILF3 expression. Together, our findings underscore the significance of macrophage ILF3 in abdominal aortic aneurysm development and suggest its potential as a promising therapeutic target for abdominal aortic aneurysms.
- 23 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Open AccessMacrophage ILF3 promotes abdominal aortic aneurysm by inducing inflammatory imbalance in male mice
Imbalance of proinflammatory and anti-inflammatory responses plays a crucial role in the progression of abdominal aortic aneurysms. ILF3, a known modulator of the innate immune response, is involved in cardiovascular diseases. This study aims to investigate the role of ILF3 in abdominal aortic aneurysm formation. Here, we use multi-omics analyzes, transgenic male mice, and multiplex immunohistochemistry to unravel the underlying involvement of ILF3 in abdominal aortic aneurysms. The results show that macrophage ILF3 deficiency attenuates abdominal aortic aneurysm progression, while elevated macrophage ILF3 exacerbates abdominal aortic aneurysm lesions. Mechanistically, we reveal that macrophagic ILF3 increases NF-κB activity by hastening the decay of p105 mRNA, leading to amplified inflammation in macrophages. Meanwhile, ILF3 represses the anti-inflammatory action by inhibiting the Keap1-Nrf2 signaling pathway through facilitating the ILF3/eIF4A1 complex-mediated enhancement of Keap1 translational efficiency. Moreover, Bardoxolone Methyl treatment alleviates the severity of abdominal aortic aneurysm lesions in the context of elevated ILF3 expression. Together, our findings underscore the significance of macrophage ILF3 in abdominal aortic aneurysm development and suggest its potential as a promising therapeutic target for abdominal aortic aneurysms.
- Open Access
- 11 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Smooth muscle NF90 deficiency ameliorates diabetic atherosclerotic calcification in male mice via FBXW7-AGER1-AGEs axis
Hyperglycemia accelerates calcification of atherosclerotic plaques in diabetic patients, and the accumulation of advanced glycation end products (AGEs) is closely related to the atherosclerotic calcification. Here, we show that hyperglycemia-mediated AGEs markedly increase vascular smooth muscle cells (VSMCs) NF90/110 activation in male diabetic patients with atherosclerotic calcified samples. VSMC-specific NF90/110 knockout in male mice decreases obviously AGEs-induced atherosclerotic calcification, along with the inhibitions of VSMC phenotypic changes to osteoblast-like cells, apoptosis, and matrix vesicle release. Mechanistically, AGEs increase the activity of NF90, which then enhances ubiquitination and degradation of AGE receptor 1 (AGER1) by stabilizing the mRNA of E3 ubiquitin ligase FBXW7, thus causing the accumulation of more AGEs and atherosclerotic calcification. Collectively, our study demonstrates the effects of VSMC NF90 in mediating the metabolic imbalance of AGEs to accelerate diabetic atherosclerotic calcification. Therefore, inhibition of VSMC NF90 may be a potential therapeutic target for diabetic atherosclerotic calcification.
- 11 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Open AccessSmooth muscle NF90 deficiency ameliorates diabetic atherosclerotic calcification in male mice via FBXW7-AGER1-AGEs axis
Hyperglycemia accelerates calcification of atherosclerotic plaques in diabetic patients, and the accumulation of advanced glycation end products (AGEs) is closely related to the atherosclerotic calcification. Here, we show that hyperglycemia-mediated AGEs markedly increase vascular smooth muscle cells (VSMCs) NF90/110 activation in male diabetic patients with atherosclerotic calcified samples. VSMC-specific NF90/110 knockout in male mice decreases obviously AGEs-induced atherosclerotic calcification, along with the inhibitions of VSMC phenotypic changes to osteoblast-like cells, apoptosis, and matrix vesicle release. Mechanistically, AGEs increase the activity of NF90, which then enhances ubiquitination and degradation of AGE receptor 1 (AGER1) by stabilizing the mRNA of E3 ubiquitin ligase FBXW7, thus causing the accumulation of more AGEs and atherosclerotic calcification. Collectively, our study demonstrates the effects of VSMC NF90 in mediating the metabolic imbalance of AGEs to accelerate diabetic atherosclerotic calcification. Therefore, inhibition of VSMC NF90 may be a potential therapeutic target for diabetic atherosclerotic calcification.
- Open Access
- 7 September 2022
- Published by Springer Nature in Molecular Medicine
- Vol. 28 (1) , 1-3
Correction: Inhibition of c-Jun N-Terminal kinase attenuates low shear stress–induced atherogenesis in apolipoprotein E–deficient mice
- 7 September 2022
- Published by Springer Nature in Molecular Medicine
- Vol. 28 (1) , 1-3
Open AccessCorrection: Inhibition of c-Jun N-Terminal kinase attenuates low shear stress–induced atherogenesis in apolipoprotein E–deficient mice
- Open Access
- 1 July 2022
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 10 (13) , 739
Salvianolic acid B alleviates neurological injury by upregulating stanniocalcin 1 expression
Original Article Salvianolic acid B alleviates neurological injury by upregulating stanniocalcin 1 expression Shao-Jie Bi, Xin-Ying Dong, Ze-Ying Wang, Shan-Ji Fu, Chang-Ling Li, Zhao-Yang Wang, Fei Xie, Xue-Ying Chen, Hao Xu, Xiao-Jun Cai, Ming-Xiang Zhang
- 1 July 2022
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 10 (13) , 739
Open AccessSalvianolic acid B alleviates neurological injury by upregulating stanniocalcin 1 expression
Original Article Salvianolic acid B alleviates neurological injury by upregulating stanniocalcin 1 expression Shao-Jie Bi, Xin-Ying Dong, Ze-Ying Wang, Shan-Ji Fu, Chang-Ling Li, Zhao-Yang Wang, Fei Xie, Xue-Ying Chen, Hao Xu, Xiao-Jun Cai, Ming-Xiang Zhang
- 1 December 2021
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 161, 39-52
ILF3 is responsible for hyperlipidemia-induced arteriosclerotic calcification by mediating BMP2 and STAT1 transcription
- 1 December 2021
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 161, 39-52
ILF3 is responsible for hyperlipidemia-induced arteriosclerotic calcification by mediating BMP2 and STAT1 transcription
- Open Access
- 1 October 2021
- Published by Elsevier in Redox Biology
- Vol. 46, 102084
PARP1 deficiency protects against hyperglycemia-induced neointimal hyperplasia by upregulating TFPI2 activity in diabetic mice
- 1 October 2021
- Published by Elsevier in Redox Biology
- Vol. 46, 102084
Open AccessPARP1 deficiency protects against hyperglycemia-induced neointimal hyperplasia by upregulating TFPI2 activity in diabetic mice